Equities research analysts expect Sage Therapeutics, Inc. (NASDAQ:SAGE) to report ($2.04) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sage Therapeutics’ earnings, with the highest EPS estimate coming in at ($1.79) and the lowest estimate coming in at ($2.35). Sage Therapeutics reported earnings per share of ($1.50) during the same quarter last year, which would indicate a negative year over year growth rate of 36%. The company is expected to issue its next earnings report on Thursday, February 22nd.

On average, analysts expect that Sage Therapeutics will report full year earnings of ($7.42) per share for the current year, with EPS estimates ranging from ($7.73) to ($7.16). For the next financial year, analysts expect that the business will post earnings of ($7.69) per share, with EPS estimates ranging from ($9.08) to ($6.43). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Sage Therapeutics.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($1.98) by $0.01. The business’s revenue for the quarter was up .0% on a year-over-year basis.

Several equities analysts recently issued reports on SAGE shares. BidaskClub downgraded shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. J P Morgan Chase & Co reissued a “buy” rating on shares of Sage Therapeutics in a report on Thursday, August 31st. Cowen cut their price target on shares of Sage Therapeutics from $100.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, September 12th. Canaccord Genuity cut their price target on shares of Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating for the company in a report on Tuesday, September 12th. Finally, SunTrust Banks reissued a “buy” rating and set a $82.00 price target (down from $95.00) on shares of Sage Therapeutics in a report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Sage Therapeutics currently has an average rating of “Buy” and a consensus price target of $171.21.

In other Sage Therapeutics news, insider Albert Robichaud sold 60,000 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $159.43, for a total value of $9,565,800.00. Following the completion of the transaction, the insider now directly owns 152,759 shares of the company’s stock, valued at $24,354,367.37. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 6.10% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Sage Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 138 shares during the last quarter. Hershey Trust Co. bought a new position in shares of Sage Therapeutics in the third quarter worth about $118,000. Oppenheimer Asset Management Inc. raised its stake in shares of Sage Therapeutics by 412.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 1,565 shares during the last quarter. Turner Investments LLC bought a new position in shares of Sage Therapeutics in the second quarter worth about $159,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of Sage Therapeutics in the second quarter worth about $175,000. 95.40% of the stock is owned by institutional investors.

Sage Therapeutics (NASDAQ SAGE) opened at $162.32 on Friday. Sage Therapeutics has a 1-year low of $44.55 and a 1-year high of $173.36.

WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/17/zacks-brokerages-anticipate-sage-therapeutics-inc-sage-will-post-earnings-of-2-04-per-share.html.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Get a free copy of the Zacks research report on Sage Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.